12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Labetuzumab-SN-38: Phase I started

Immunomedics disclosed in its fiscal year 2011 earnings ending June 30 that it began an open-label, dose-escalation Phase I trial evaluating IV labetuzumab-SN-38 every...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >